nodes	percent_of_prediction	percent_of_DWPC	metapath
Fludarabine—RRM1—larynx—esophageal cancer	0.0566	0.269	CbGeAlD
Fludarabine—DCK—Pyrimidine salvage reactions—TYMP—esophageal cancer	0.025	0.076	CbGpPWpGaD
Fludarabine—SLC28A3—trachea—esophageal cancer	0.0162	0.0768	CbGeAlD
Fludarabine—Pulmonary toxicity—Cisplatin—esophageal cancer	0.0142	0.0315	CcSEcCtD
Fludarabine—SLC28A3—digestive system—esophageal cancer	0.0139	0.0661	CbGeAlD
Fludarabine—RRM1—Fluoropyrimidine Activity—XRCC3—esophageal cancer	0.0137	0.0417	CbGpPWpGaD
Fludarabine—Lymphoproliferative disorder—Methotrexate—esophageal cancer	0.0131	0.029	CcSEcCtD
Fludarabine—X-linked lymphoproliferative syndrome—Methotrexate—esophageal cancer	0.0131	0.029	CcSEcCtD
Fludarabine—SLC29A1—Fluoropyrimidine Activity—XRCC3—esophageal cancer	0.0125	0.0381	CbGpPWpGaD
Fludarabine—SLC28A3—lung—esophageal cancer	0.0116	0.0552	CbGeAlD
Fludarabine—RRM1—Fluoropyrimidine Activity—TYMP—esophageal cancer	0.0115	0.0349	CbGpPWpGaD
Fludarabine—DCK—Pyrimidine metabolism—TYMP—esophageal cancer	0.0114	0.0347	CbGpPWpGaD
Fludarabine—Fibrosis—Cisplatin—esophageal cancer	0.0113	0.025	CcSEcCtD
Fludarabine—SLC29A1—Fluoropyrimidine Activity—TYMP—esophageal cancer	0.0105	0.032	CbGpPWpGaD
Fludarabine—Immunodeficiency—Methotrexate—esophageal cancer	0.0102	0.0226	CcSEcCtD
Fludarabine—RRM1—bronchus—esophageal cancer	0.0101	0.0477	CbGeAlD
Fludarabine—RRM1—smooth muscle tissue—esophageal cancer	0.00984	0.0467	CbGeAlD
Fludarabine—Phlebitis—Carboplatin—esophageal cancer	0.00927	0.0205	CcSEcCtD
Fludarabine—Fibrosis—Capecitabine—esophageal cancer	0.00833	0.0184	CcSEcCtD
Fludarabine—Neurotoxicity—Cisplatin—esophageal cancer	0.00833	0.0184	CcSEcCtD
Fludarabine—SLC29A1—bronchus—esophageal cancer	0.00818	0.0388	CbGeAlD
Fludarabine—POLA1—lung—esophageal cancer	0.00817	0.0388	CbGeAlD
Fludarabine—RRM1—Fluoropyrimidine Activity—CYP2A6—esophageal cancer	0.00797	0.0242	CbGpPWpGaD
Fludarabine—DCK—bronchus—esophageal cancer	0.00781	0.0371	CbGeAlD
Fludarabine—Pulmonary toxicity—Methotrexate—esophageal cancer	0.0078	0.0173	CcSEcCtD
Fludarabine—RRM1—digestive system—esophageal cancer	0.00777	0.0369	CbGeAlD
Fludarabine—SLC29A1—trachea—esophageal cancer	0.00734	0.0348	CbGeAlD
Fludarabine—SLC29A1—Fluoropyrimidine Activity—CYP2A6—esophageal cancer	0.00729	0.0222	CbGpPWpGaD
Fludarabine—DCK—trachea—esophageal cancer	0.00701	0.0333	CbGeAlD
Fludarabine—Myelosuppression—Cisplatin—esophageal cancer	0.00688	0.0152	CcSEcCtD
Fludarabine—Alveolitis allergic—Methotrexate—esophageal cancer	0.00679	0.015	CcSEcCtD
Fludarabine—RRM1—lung—esophageal cancer	0.00649	0.0308	CbGeAlD
Fludarabine—RRM1—Fluoropyrimidine Activity—SMUG1—esophageal cancer	0.00649	0.0197	CbGpPWpGaD
Fludarabine—Tumour lysis syndrome—Methotrexate—esophageal cancer	0.00638	0.0141	CcSEcCtD
Fludarabine—SLC29A1—digestive system—esophageal cancer	0.00632	0.03	CbGeAlD
Fludarabine—Fibrosis—Methotrexate—esophageal cancer	0.0062	0.0137	CcSEcCtD
Fludarabine—Neurotoxicity—Capecitabine—esophageal cancer	0.00614	0.0136	CcSEcCtD
Fludarabine—DCK—digestive system—esophageal cancer	0.00603	0.0286	CbGeAlD
Fludarabine—SLC29A1—Fluoropyrimidine Activity—SMUG1—esophageal cancer	0.00593	0.018	CbGpPWpGaD
Fludarabine—Blindness—Cisplatin—esophageal cancer	0.00583	0.0129	CcSEcCtD
Fludarabine—Pericardial effusion—Capecitabine—esophageal cancer	0.0058	0.0128	CcSEcCtD
Fludarabine—RRM1—Nucleotide metabolism—TYMP—esophageal cancer	0.00577	0.0176	CbGpPWpGaD
Fludarabine—POLA1—lymph node—esophageal cancer	0.00559	0.0265	CbGeAlD
Fludarabine—RRM1—E2F transcription factor network—XRCC1—esophageal cancer	0.00528	0.0161	CbGpPWpGaD
Fludarabine—SLC29A1—lung—esophageal cancer	0.00528	0.025	CbGeAlD
Fludarabine—Optic neuritis—Cisplatin—esophageal cancer	0.00525	0.0116	CcSEcCtD
Fludarabine—DCK—lung—esophageal cancer	0.00504	0.0239	CbGeAlD
Fludarabine—Transient ischaemic attack—Capecitabine—esophageal cancer	0.00472	0.0104	CcSEcCtD
Fludarabine—Neurotoxicity—Methotrexate—esophageal cancer	0.00457	0.0101	CcSEcCtD
Fludarabine—POLA1—Inhibition of replication initiation of damaged DNA by RB1/E2F1—RB1—esophageal cancer	0.00445	0.0135	CbGpPWpGaD
Fludarabine—DCK—Nucleotide metabolism—TYMP—esophageal cancer	0.00444	0.0135	CbGpPWpGaD
Fludarabine—RRM1—lymph node—esophageal cancer	0.00444	0.0211	CbGeAlD
Fludarabine—Opportunistic infection—Methotrexate—esophageal cancer	0.0044	0.00974	CcSEcCtD
Fludarabine—Pericardial effusion—Methotrexate—esophageal cancer	0.00432	0.00956	CcSEcCtD
Fludarabine—Mucosal inflammation—Capecitabine—esophageal cancer	0.0043	0.00952	CcSEcCtD
Fludarabine—Pulmonary fibrosis—Methotrexate—esophageal cancer	0.00403	0.00892	CcSEcCtD
Fludarabine—Deep vein thrombosis—Capecitabine—esophageal cancer	0.00391	0.00866	CcSEcCtD
Fludarabine—Infection—Carboplatin—esophageal cancer	0.0039	0.00864	CcSEcCtD
Fludarabine—Lung infiltration—Methotrexate—esophageal cancer	0.00378	0.00836	CcSEcCtD
Fludarabine—Respiratory distress—Capecitabine—esophageal cancer	0.00375	0.00829	CcSEcCtD
Fludarabine—Supraventricular tachycardia—Capecitabine—esophageal cancer	0.00363	0.00804	CcSEcCtD
Fludarabine—Adenosine monophosphate—PDE4D—esophageal cancer	0.00362	0.414	CrCbGaD
Fludarabine—SLC29A1—lymph node—esophageal cancer	0.00361	0.0171	CbGeAlD
Fludarabine—Bone marrow depression—Capecitabine—esophageal cancer	0.00353	0.00781	CcSEcCtD
Fludarabine—Hyperuricaemia—Cisplatin—esophageal cancer	0.00348	0.00771	CcSEcCtD
Fludarabine—Haemoglobin decreased—Capecitabine—esophageal cancer	0.00346	0.00766	CcSEcCtD
Fludarabine—DCK—lymph node—esophageal cancer	0.00345	0.0164	CbGeAlD
Fludarabine—RRM1—Integrated Pancreatic Cancer Pathway—FKBP1A—esophageal cancer	0.00344	0.0105	CbGpPWpGaD
Fludarabine—Hearing impaired—Cisplatin—esophageal cancer	0.00339	0.00751	CcSEcCtD
Fludarabine—SLC28A3—SLC-mediated transmembrane transport—SLC39A6—esophageal cancer	0.00338	0.0103	CbGpPWpGaD
Fludarabine—Pain—Carboplatin—esophageal cancer	0.00336	0.00743	CcSEcCtD
Fludarabine—Blood uric acid increased—Cisplatin—esophageal cancer	0.00329	0.00728	CcSEcCtD
Fludarabine—Haemoptysis—Capecitabine—esophageal cancer	0.00322	0.00712	CcSEcCtD
Fludarabine—Mucosal inflammation—Methotrexate—esophageal cancer	0.0032	0.00708	CcSEcCtD
Fludarabine—Hyperkalaemia—Cisplatin—esophageal cancer	0.00317	0.00702	CcSEcCtD
Fludarabine—Herpes zoster—Capecitabine—esophageal cancer	0.00316	0.007	CcSEcCtD
Fludarabine—Osteoporosis—Methotrexate—esophageal cancer	0.00316	0.007	CcSEcCtD
Fludarabine—Body temperature increased—Carboplatin—esophageal cancer	0.0031	0.00687	CcSEcCtD
Fludarabine—SLC28A3—SLC-mediated transmembrane transport—SLC30A7—esophageal cancer	0.00309	0.00941	CbGpPWpGaD
Fludarabine—RRM1—Retinoblastoma (RB) in Cancer—HMGB1—esophageal cancer	0.00304	0.00924	CbGpPWpGaD
Fludarabine—Adenosine triphosphate—ABL1—esophageal cancer	0.00303	0.347	CrCbGaD
Fludarabine—POLA1—E2F transcription factor network—XRCC1—esophageal cancer	0.00297	0.00904	CbGpPWpGaD
Fludarabine—Deep vein thrombosis—Methotrexate—esophageal cancer	0.00291	0.00645	CcSEcCtD
Fludarabine—Hypoxia—Methotrexate—esophageal cancer	0.00279	0.00617	CcSEcCtD
Fludarabine—Phlebitis—Cisplatin—esophageal cancer	0.00272	0.00602	CcSEcCtD
Fludarabine—POLA1—Telomere Maintenance—HIST1H2BM—esophageal cancer	0.00271	0.00826	CbGpPWpGaD
Fludarabine—Proteinuria—Capecitabine—esophageal cancer	0.00271	0.006	CcSEcCtD
Fludarabine—RRM1—Integrated Pancreatic Cancer Pathway—BBC3—esophageal cancer	0.00267	0.00813	CbGpPWpGaD
Fludarabine—Protein urine present—Capecitabine—esophageal cancer	0.00267	0.00591	CcSEcCtD
Fludarabine—Bone marrow depression—Methotrexate—esophageal cancer	0.00262	0.00581	CcSEcCtD
Fludarabine—Deafness—Cisplatin—esophageal cancer	0.00262	0.0058	CcSEcCtD
Fludarabine—Hypocalcaemia—Capecitabine—esophageal cancer	0.0026	0.00576	CcSEcCtD
Fludarabine—Cardiac failure congestive—Cisplatin—esophageal cancer	0.00258	0.00572	CcSEcCtD
Fludarabine—SLC29A1—SLC-mediated transmembrane transport—SLC39A6—esophageal cancer	0.00252	0.00767	CbGpPWpGaD
Fludarabine—RRM1—Retinoblastoma (RB) in Cancer—ABL1—esophageal cancer	0.00251	0.00765	CbGpPWpGaD
Fludarabine—Hearing impaired—Capecitabine—esophageal cancer	0.0025	0.00554	CcSEcCtD
Fludarabine—Cerebrovascular accident—Cisplatin—esophageal cancer	0.00239	0.00529	CcSEcCtD
Fludarabine—Herpes zoster—Methotrexate—esophageal cancer	0.00235	0.00521	CcSEcCtD
Fludarabine—Gastrointestinal haemorrhage—Cisplatin—esophageal cancer	0.00234	0.00519	CcSEcCtD
Fludarabine—DCK—Retinoblastoma (RB) in Cancer—HMGB1—esophageal cancer	0.00234	0.00711	CbGpPWpGaD
Fludarabine—SLC29A1—SLC-mediated transmembrane transport—SLC30A7—esophageal cancer	0.00231	0.00701	CbGpPWpGaD
Fludarabine—POLA1—Chromosome Maintenance—HIST1H2BM—esophageal cancer	0.00226	0.00688	CbGpPWpGaD
Fludarabine—Dehydration—Cisplatin—esophageal cancer	0.00218	0.00483	CcSEcCtD
Fludarabine—Oesophagitis—Capecitabine—esophageal cancer	0.00217	0.00481	CcSEcCtD
Fludarabine—POLA1—DNA Replication Pre-Initiation—PSME1—esophageal cancer	0.00204	0.00621	CbGpPWpGaD
Fludarabine—POLA1—DNA Replication Pre-Initiation—PSME2—esophageal cancer	0.00204	0.00621	CbGpPWpGaD
Fludarabine—Proteinuria—Methotrexate—esophageal cancer	0.00202	0.00446	CcSEcCtD
Fludarabine—Phlebitis—Capecitabine—esophageal cancer	0.00201	0.00444	CcSEcCtD
Fludarabine—Sleep disorder—Capecitabine—esophageal cancer	0.002	0.00442	CcSEcCtD
Fludarabine—Protein urine present—Methotrexate—esophageal cancer	0.00199	0.0044	CcSEcCtD
Fludarabine—POLA1—E2F mediated regulation of DNA replication—RB1—esophageal cancer	0.00198	0.00603	CbGpPWpGaD
Fludarabine—Sweating increased—Cisplatin—esophageal cancer	0.00197	0.00437	CcSEcCtD
Fludarabine—POLA1—Integrated Pancreatic Cancer Pathway—FKBP1A—esophageal cancer	0.00194	0.0059	CbGpPWpGaD
Fludarabine—DCK—Retinoblastoma (RB) in Cancer—ABL1—esophageal cancer	0.00193	0.00588	CbGpPWpGaD
Fludarabine—Deafness—Capecitabine—esophageal cancer	0.00193	0.00428	CcSEcCtD
Fludarabine—SLC28A3—Transmembrane transport of small molecules—SLC10A2—esophageal cancer	0.00193	0.00586	CbGpPWpGaD
Fludarabine—Pancytopenia—Cisplatin—esophageal cancer	0.00192	0.00426	CcSEcCtD
Fludarabine—Hepatic failure—Capecitabine—esophageal cancer	0.00192	0.00426	CcSEcCtD
Fludarabine—Hyperuricaemia—Methotrexate—esophageal cancer	0.00191	0.00423	CcSEcCtD
Fludarabine—RRM1—E2F transcription factor network—CREBBP—esophageal cancer	0.00187	0.00569	CbGpPWpGaD
Fludarabine—RRM1—E2F transcription factor network—RB1—esophageal cancer	0.00187	0.00567	CbGpPWpGaD
Fludarabine—RRM1—Integrated Pancreatic Cancer Pathway—ANXA1—esophageal cancer	0.00182	0.00553	CbGpPWpGaD
Fludarabine—SLC28A3—Transmembrane transport of small molecules—ATP1B2—esophageal cancer	0.00181	0.00551	CbGpPWpGaD
Fludarabine—Blood uric acid increased—Methotrexate—esophageal cancer	0.0018	0.00399	CcSEcCtD
Fludarabine—Respiratory failure—Methotrexate—esophageal cancer	0.0018	0.00399	CcSEcCtD
Fludarabine—POLA1—Synthesis of DNA—PSME2—esophageal cancer	0.00178	0.00542	CbGpPWpGaD
Fludarabine—POLA1—Synthesis of DNA—PSME1—esophageal cancer	0.00178	0.00542	CbGpPWpGaD
Fludarabine—Acute coronary syndrome—Cisplatin—esophageal cancer	0.00178	0.00394	CcSEcCtD
Fludarabine—Renal failure—Cisplatin—esophageal cancer	0.00178	0.00393	CcSEcCtD
Fludarabine—Myocardial infarction—Cisplatin—esophageal cancer	0.00177	0.00392	CcSEcCtD
Fludarabine—Neuropathy peripheral—Cisplatin—esophageal cancer	0.00177	0.00392	CcSEcCtD
Fludarabine—Cardiac failure—Capecitabine—esophageal cancer	0.00177	0.00392	CcSEcCtD
Fludarabine—Cerebrovascular accident—Capecitabine—esophageal cancer	0.00176	0.0039	CcSEcCtD
Fludarabine—Stomatitis—Cisplatin—esophageal cancer	0.00176	0.0039	CcSEcCtD
Fludarabine—Gastrointestinal haemorrhage—Capecitabine—esophageal cancer	0.00173	0.00382	CcSEcCtD
Fludarabine—RRM1—Fluoropyrimidine Activity—TP53—esophageal cancer	0.00172	0.00524	CbGpPWpGaD
Fludarabine—SLC28A3—Transmembrane transport of small molecules—SLC39A6—esophageal cancer	0.00172	0.00523	CbGpPWpGaD
Fludarabine—POLA1—Retinoblastoma (RB) in Cancer—HMGB1—esophageal cancer	0.00171	0.00521	CbGpPWpGaD
Fludarabine—POLA1—DNA Replication—PSME1—esophageal cancer	0.00167	0.00509	CbGpPWpGaD
Fludarabine—POLA1—DNA Replication—PSME2—esophageal cancer	0.00167	0.00509	CbGpPWpGaD
Fludarabine—RRM1—Integrated Pancreatic Cancer Pathway—BUB1B—esophageal cancer	0.00166	0.00506	CbGpPWpGaD
Fludarabine—RRM1—E2F transcription factor network—CDKN2A—esophageal cancer	0.00164	0.00499	CbGpPWpGaD
Fludarabine—SLC28A3—Transmembrane transport of small molecules—AQP3—esophageal cancer	0.00164	0.00499	CbGpPWpGaD
Fludarabine—RRM1—Retinoblastoma (RB) in Cancer—RB1—esophageal cancer	0.00162	0.00493	CbGpPWpGaD
Fludarabine—Coma—Methotrexate—esophageal cancer	0.00162	0.00358	CcSEcCtD
Fludarabine—POLA1—G1/S Transition—PSME2—esophageal cancer	0.00161	0.0049	CbGpPWpGaD
Fludarabine—POLA1—G1/S Transition—PSME1—esophageal cancer	0.00161	0.0049	CbGpPWpGaD
Fludarabine—Dehydration—Capecitabine—esophageal cancer	0.00161	0.00356	CcSEcCtD
Fludarabine—Liver function test abnormal—Capecitabine—esophageal cancer	0.00159	0.00353	CcSEcCtD
Fludarabine—RRM1—Integrated Pancreatic Cancer Pathway—CHEK2—esophageal cancer	0.00158	0.00481	CbGpPWpGaD
Fludarabine—SLC29A1—Fluoropyrimidine Activity—TP53—esophageal cancer	0.00158	0.00479	CbGpPWpGaD
Fludarabine—SLC28A3—Transmembrane transport of small molecules—SLC30A7—esophageal cancer	0.00157	0.00478	CbGpPWpGaD
Fludarabine—SLC28A3—Transmembrane transport of small molecules—ATP4A—esophageal cancer	0.00157	0.00478	CbGpPWpGaD
Fludarabine—Visual impairment—Cisplatin—esophageal cancer	0.00156	0.00346	CcSEcCtD
Fludarabine—Toxic epidermal necrolysis—Capecitabine—esophageal cancer	0.00156	0.00344	CcSEcCtD
Fludarabine—Adenosine triphosphate—ABCC2—esophageal cancer	0.00152	0.174	CrCbGaD
Fludarabine—POLA1—Integrated Pancreatic Cancer Pathway—BBC3—esophageal cancer	0.00151	0.00458	CbGpPWpGaD
Fludarabine—Dysphagia—Capecitabine—esophageal cancer	0.00149	0.00331	CcSEcCtD
Fludarabine—POLA1—S Phase—PSME1—esophageal cancer	0.00146	0.00445	CbGpPWpGaD
Fludarabine—POLA1—S Phase—PSME2—esophageal cancer	0.00146	0.00445	CbGpPWpGaD
Fludarabine—Angina pectoris—Capecitabine—esophageal cancer	0.00145	0.00322	CcSEcCtD
Fludarabine—Sweating increased—Capecitabine—esophageal cancer	0.00145	0.00322	CcSEcCtD
Fludarabine—Arrhythmia—Cisplatin—esophageal cancer	0.00145	0.00321	CcSEcCtD
Fludarabine—SLC29A1—Transmembrane transport of small molecules—SLC10A2—esophageal cancer	0.00144	0.00437	CbGpPWpGaD
Fludarabine—Bronchitis—Capecitabine—esophageal cancer	0.00144	0.00318	CcSEcCtD
Fludarabine—Alopecia—Cisplatin—esophageal cancer	0.00143	0.00317	CcSEcCtD
Fludarabine—Hepatic failure—Methotrexate—esophageal cancer	0.00143	0.00317	CcSEcCtD
Fludarabine—Pancytopenia—Capecitabine—esophageal cancer	0.00142	0.00314	CcSEcCtD
Fludarabine—POLA1—Retinoblastoma (RB) in Cancer—ABL1—esophageal cancer	0.00142	0.00431	CbGpPWpGaD
Fludarabine—Malnutrition—Cisplatin—esophageal cancer	0.00141	0.00312	CcSEcCtD
Fludarabine—Neutropenia—Capecitabine—esophageal cancer	0.0014	0.00309	CcSEcCtD
Fludarabine—Dysuria—Capecitabine—esophageal cancer	0.0014	0.00309	CcSEcCtD
Fludarabine—Upper respiratory tract infection—Capecitabine—esophageal cancer	0.00139	0.00307	CcSEcCtD
Fludarabine—POLA1—Mitotic G1-G1/S phases—PSME2—esophageal cancer	0.00136	0.00413	CbGpPWpGaD
Fludarabine—POLA1—Mitotic G1-G1/S phases—PSME1—esophageal cancer	0.00136	0.00413	CbGpPWpGaD
Fludarabine—Visual disturbance—Methotrexate—esophageal cancer	0.00136	0.003	CcSEcCtD
Fludarabine—SLC29A1—Transmembrane transport of small molecules—ATP1B2—esophageal cancer	0.00135	0.00411	CbGpPWpGaD
Fludarabine—Hyperglycaemia—Capecitabine—esophageal cancer	0.00135	0.00298	CcSEcCtD
Fludarabine—RRM1—E2F transcription factor network—CDKN1A—esophageal cancer	0.00134	0.00408	CbGpPWpGaD
Fludarabine—RRM1—Integrated Pancreatic Cancer Pathway—ABL1—esophageal cancer	0.00134	0.00408	CbGpPWpGaD
Fludarabine—POLA1—Cell Cycle, Mitotic—AJUBA—esophageal cancer	0.00134	0.00407	CbGpPWpGaD
Fludarabine—Pneumonia—Capecitabine—esophageal cancer	0.00134	0.00296	CcSEcCtD
Fludarabine—Stevens-Johnson syndrome—Capecitabine—esophageal cancer	0.00132	0.00292	CcSEcCtD
Fludarabine—Acute coronary syndrome—Capecitabine—esophageal cancer	0.00131	0.00291	CcSEcCtD
Fludarabine—Cerebrovascular accident—Methotrexate—esophageal cancer	0.00131	0.00291	CcSEcCtD
Fludarabine—Ill-defined disorder—Cisplatin—esophageal cancer	0.00131	0.0029	CcSEcCtD
Fludarabine—Renal failure—Capecitabine—esophageal cancer	0.00131	0.0029	CcSEcCtD
Fludarabine—Neuropathy peripheral—Capecitabine—esophageal cancer	0.0013	0.00289	CcSEcCtD
Fludarabine—Myocardial infarction—Capecitabine—esophageal cancer	0.0013	0.00289	CcSEcCtD
Fludarabine—Anaemia—Cisplatin—esophageal cancer	0.0013	0.00289	CcSEcCtD
Fludarabine—RRM1—Integrated Pancreatic Cancer Pathway—ABCB1—esophageal cancer	0.0013	0.00395	CbGpPWpGaD
Fludarabine—RRM1—Integrated Pancreatic Cancer Pathway—SMAD4—esophageal cancer	0.0013	0.00395	CbGpPWpGaD
Fludarabine—Stomatitis—Capecitabine—esophageal cancer	0.0013	0.00287	CcSEcCtD
Fludarabine—Urinary tract infection—Capecitabine—esophageal cancer	0.00129	0.00286	CcSEcCtD
Fludarabine—SLC29A1—Transmembrane transport of small molecules—SLC39A6—esophageal cancer	0.00128	0.0039	CbGpPWpGaD
Fludarabine—RRM1—E2F transcription factor network—EP300—esophageal cancer	0.00128	0.00388	CbGpPWpGaD
Fludarabine—Malaise—Cisplatin—esophageal cancer	0.00127	0.00282	CcSEcCtD
Fludarabine—Haematuria—Capecitabine—esophageal cancer	0.00127	0.00281	CcSEcCtD
Fludarabine—Leukopenia—Cisplatin—esophageal cancer	0.00126	0.0028	CcSEcCtD
Fludarabine—Epistaxis—Capecitabine—esophageal cancer	0.00126	0.00278	CcSEcCtD
Fludarabine—DCK—Retinoblastoma (RB) in Cancer—RB1—esophageal cancer	0.00125	0.00379	CbGpPWpGaD
Fludarabine—RRM1—Integrated Pancreatic Cancer Pathway—BAX—esophageal cancer	0.00123	0.00373	CbGpPWpGaD
Fludarabine—Convulsion—Cisplatin—esophageal cancer	0.00122	0.00271	CcSEcCtD
Fludarabine—SLC29A1—Transmembrane transport of small molecules—AQP3—esophageal cancer	0.00122	0.00372	CbGpPWpGaD
Fludarabine—RRM1—Retinoblastoma (RB) in Cancer—CCND1—esophageal cancer	0.0012	0.00366	CbGpPWpGaD
Fludarabine—Myalgia—Cisplatin—esophageal cancer	0.0012	0.00266	CcSEcCtD
Fludarabine—Haemoglobin—Capecitabine—esophageal cancer	0.0012	0.00266	CcSEcCtD
Fludarabine—POLA1—Cell Cycle—AJUBA—esophageal cancer	0.0012	0.00364	CbGpPWpGaD
Fludarabine—Haemorrhage—Capecitabine—esophageal cancer	0.0012	0.00265	CcSEcCtD
Fludarabine—SLC28A3—Transmembrane transport of small molecules—ABCC2—esophageal cancer	0.00119	0.00362	CbGpPWpGaD
Fludarabine—Hypoaesthesia—Capecitabine—esophageal cancer	0.00119	0.00263	CcSEcCtD
Fludarabine—Liver function test abnormal—Methotrexate—esophageal cancer	0.00119	0.00263	CcSEcCtD
Fludarabine—Discomfort—Cisplatin—esophageal cancer	0.00119	0.00263	CcSEcCtD
Fludarabine—Pharyngitis—Capecitabine—esophageal cancer	0.00119	0.00263	CcSEcCtD
Fludarabine—SLC29A1—Transmembrane transport of small molecules—ATP4A—esophageal cancer	0.00117	0.00356	CbGpPWpGaD
Fludarabine—SLC29A1—Transmembrane transport of small molecules—SLC30A7—esophageal cancer	0.00117	0.00356	CbGpPWpGaD
Fludarabine—RRM1—Retinoblastoma (RB) in Cancer—CDKN1A—esophageal cancer	0.00116	0.00354	CbGpPWpGaD
Fludarabine—Toxic epidermal necrolysis—Methotrexate—esophageal cancer	0.00116	0.00256	CcSEcCtD
Fludarabine—Oedema—Cisplatin—esophageal cancer	0.00115	0.00255	CcSEcCtD
Fludarabine—Anaphylactic shock—Cisplatin—esophageal cancer	0.00115	0.00255	CcSEcCtD
Fludarabine—Visual impairment—Capecitabine—esophageal cancer	0.00115	0.00255	CcSEcCtD
Fludarabine—Infection—Cisplatin—esophageal cancer	0.00114	0.00253	CcSEcCtD
Fludarabine—Erythema multiforme—Capecitabine—esophageal cancer	0.00113	0.0025	CcSEcCtD
Fludarabine—Nervous system disorder—Cisplatin—esophageal cancer	0.00113	0.0025	CcSEcCtD
Fludarabine—Thrombocytopenia—Cisplatin—esophageal cancer	0.00113	0.0025	CcSEcCtD
Fludarabine—Hyperhidrosis—Cisplatin—esophageal cancer	0.00111	0.00247	CcSEcCtD
Fludarabine—RRM1—E2F transcription factor network—MYC—esophageal cancer	0.00111	0.00338	CbGpPWpGaD
Fludarabine—Anorexia—Cisplatin—esophageal cancer	0.0011	0.00243	CcSEcCtD
Fludarabine—POLA1—Cell Cycle—MLH3—esophageal cancer	0.00108	0.00329	CbGpPWpGaD
Fludarabine—SLC28A3—Transmembrane transport of small molecules—GNG7—esophageal cancer	0.00108	0.00329	CbGpPWpGaD
Fludarabine—Chills—Capecitabine—esophageal cancer	0.00107	0.00237	CcSEcCtD
Fludarabine—Arrhythmia—Capecitabine—esophageal cancer	0.00107	0.00236	CcSEcCtD
Fludarabine—Alopecia—Capecitabine—esophageal cancer	0.00106	0.00234	CcSEcCtD
Fludarabine—Pancytopenia—Methotrexate—esophageal cancer	0.00106	0.00234	CcSEcCtD
Fludarabine—POLA1—E2F transcription factor network—CREBBP—esophageal cancer	0.00105	0.00321	CbGpPWpGaD
Fludarabine—POLA1—E2F transcription factor network—RB1—esophageal cancer	0.00105	0.0032	CbGpPWpGaD
Fludarabine—Musculoskeletal discomfort—Cisplatin—esophageal cancer	0.00105	0.00232	CcSEcCtD
Fludarabine—Malnutrition—Capecitabine—esophageal cancer	0.00104	0.0023	CcSEcCtD
Fludarabine—Neutropenia—Methotrexate—esophageal cancer	0.00104	0.0023	CcSEcCtD
Fludarabine—Dysuria—Methotrexate—esophageal cancer	0.00104	0.0023	CcSEcCtD
Fludarabine—Paraesthesia—Cisplatin—esophageal cancer	0.00103	0.00229	CcSEcCtD
Fludarabine—Upper respiratory tract infection—Methotrexate—esophageal cancer	0.00103	0.00229	CcSEcCtD
Fludarabine—Dyspnoea—Cisplatin—esophageal cancer	0.00103	0.00227	CcSEcCtD
Fludarabine—POLA1—Integrated Pancreatic Cancer Pathway—ANXA1—esophageal cancer	0.00102	0.00311	CbGpPWpGaD
Fludarabine—Decreased appetite—Cisplatin—esophageal cancer	0.001	0.00222	CcSEcCtD
Fludarabine—Pneumonia—Methotrexate—esophageal cancer	0.000997	0.00221	CcSEcCtD
Fludarabine—Gastrointestinal disorder—Cisplatin—esophageal cancer	0.000994	0.0022	CcSEcCtD
Fludarabine—Pain—Cisplatin—esophageal cancer	0.000985	0.00218	CcSEcCtD
Fludarabine—Stevens-Johnson syndrome—Methotrexate—esophageal cancer	0.000982	0.00218	CcSEcCtD
Fludarabine—Renal failure—Methotrexate—esophageal cancer	0.000974	0.00216	CcSEcCtD
Fludarabine—Stomatitis—Methotrexate—esophageal cancer	0.000966	0.00214	CcSEcCtD
Fludarabine—RRM1—Retinoblastoma (RB) in Cancer—MYC—esophageal cancer	0.000966	0.00294	CbGpPWpGaD
Fludarabine—Ill-defined disorder—Capecitabine—esophageal cancer	0.000965	0.00214	CcSEcCtD
Fludarabine—Anaemia—Capecitabine—esophageal cancer	0.000961	0.00213	CcSEcCtD
Fludarabine—Feeling abnormal—Cisplatin—esophageal cancer	0.000949	0.0021	CcSEcCtD
Fludarabine—Haematuria—Methotrexate—esophageal cancer	0.000945	0.00209	CcSEcCtD
Fludarabine—Malaise—Capecitabine—esophageal cancer	0.000938	0.00208	CcSEcCtD
Fludarabine—POLA1—Integrated Pancreatic Cancer Pathway—BUB1B—esophageal cancer	0.000936	0.00285	CbGpPWpGaD
Fludarabine—Epistaxis—Methotrexate—esophageal cancer	0.000935	0.00207	CcSEcCtD
Fludarabine—Leukopenia—Capecitabine—esophageal cancer	0.000931	0.00206	CcSEcCtD
Fludarabine—DCK—Retinoblastoma (RB) in Cancer—CCND1—esophageal cancer	0.000926	0.00282	CbGpPWpGaD
Fludarabine—POLA1—E2F transcription factor network—CDKN2A—esophageal cancer	0.000924	0.00281	CbGpPWpGaD
Fludarabine—POLA1—Retinoblastoma (RB) in Cancer—RB1—esophageal cancer	0.000913	0.00278	CbGpPWpGaD
Fludarabine—Body temperature increased—Cisplatin—esophageal cancer	0.00091	0.00202	CcSEcCtD
Fludarabine—Cough—Capecitabine—esophageal cancer	0.000908	0.00201	CcSEcCtD
Fludarabine—DCK—Retinoblastoma (RB) in Cancer—CDKN1A—esophageal cancer	0.000896	0.00273	CbGpPWpGaD
Fludarabine—Haemoglobin—Methotrexate—esophageal cancer	0.000894	0.00198	CcSEcCtD
Fludarabine—POLA1—Integrated Pancreatic Cancer Pathway—CHEK2—esophageal cancer	0.000891	0.00271	CbGpPWpGaD
Fludarabine—Haemorrhage—Methotrexate—esophageal cancer	0.00089	0.00197	CcSEcCtD
Fludarabine—SLC29A1—Transmembrane transport of small molecules—ABCC2—esophageal cancer	0.000888	0.0027	CbGpPWpGaD
Fludarabine—Arthralgia—Capecitabine—esophageal cancer	0.000886	0.00196	CcSEcCtD
Fludarabine—Myalgia—Capecitabine—esophageal cancer	0.000886	0.00196	CcSEcCtD
Fludarabine—Pharyngitis—Methotrexate—esophageal cancer	0.000883	0.00195	CcSEcCtD
Fludarabine—Discomfort—Capecitabine—esophageal cancer	0.000875	0.00194	CcSEcCtD
Fludarabine—RRM1—Integrated Pancreatic Cancer Pathway—CASP8—esophageal cancer	0.000871	0.00265	CbGpPWpGaD
Fludarabine—RRM1—Integrated Pancreatic Cancer Pathway—CREBBP—esophageal cancer	0.000867	0.00264	CbGpPWpGaD
Fludarabine—RRM1—Metabolism—SLC52A3—esophageal cancer	0.000866	0.00263	CbGpPWpGaD
Fludarabine—RRM1—Metabolism—BLVRB—esophageal cancer	0.000866	0.00263	CbGpPWpGaD
Fludarabine—POLA1—Mitotic M-M/G1 phases—HIST1H2BM—esophageal cancer	0.000858	0.00261	CbGpPWpGaD
Fludarabine—Visual impairment—Methotrexate—esophageal cancer	0.000857	0.0019	CcSEcCtD
Fludarabine—Confusional state—Capecitabine—esophageal cancer	0.000856	0.0019	CcSEcCtD
Fludarabine—Oedema—Capecitabine—esophageal cancer	0.000849	0.00188	CcSEcCtD
Fludarabine—Hypersensitivity—Cisplatin—esophageal cancer	0.000849	0.00188	CcSEcCtD
Fludarabine—POLA1—Synthesis of DNA—RB1—esophageal cancer	0.000844	0.00257	CbGpPWpGaD
Fludarabine—Infection—Capecitabine—esophageal cancer	0.000843	0.00187	CcSEcCtD
Fludarabine—Erythema multiforme—Methotrexate—esophageal cancer	0.000841	0.00186	CcSEcCtD
Fludarabine—Nervous system disorder—Capecitabine—esophageal cancer	0.000833	0.00184	CcSEcCtD
Fludarabine—Thrombocytopenia—Capecitabine—esophageal cancer	0.000831	0.00184	CcSEcCtD
Fludarabine—Asthenia—Cisplatin—esophageal cancer	0.000826	0.00183	CcSEcCtD
Fludarabine—Hyperhidrosis—Capecitabine—esophageal cancer	0.000821	0.00182	CcSEcCtD
Fludarabine—Anorexia—Capecitabine—esophageal cancer	0.000809	0.00179	CcSEcCtD
Fludarabine—SLC29A1—Transmembrane transport of small molecules—GNG7—esophageal cancer	0.000806	0.00245	CbGpPWpGaD
Fludarabine—Chills—Methotrexate—esophageal cancer	0.000798	0.00177	CcSEcCtD
Fludarabine—RRM1—Retinoblastoma (RB) in Cancer—TP53—esophageal cancer	0.000793	0.00241	CbGpPWpGaD
Fludarabine—POLA1—DNA Replication—RB1—esophageal cancer	0.000792	0.00241	CbGpPWpGaD
Fludarabine—Diarrhoea—Cisplatin—esophageal cancer	0.000788	0.00174	CcSEcCtD
Fludarabine—Alopecia—Methotrexate—esophageal cancer	0.000786	0.00174	CcSEcCtD
Fludarabine—Malnutrition—Methotrexate—esophageal cancer	0.000774	0.00171	CcSEcCtD
Fludarabine—Musculoskeletal discomfort—Capecitabine—esophageal cancer	0.000774	0.00171	CcSEcCtD
Fludarabine—POLA1—G1/S Transition—RB1—esophageal cancer	0.000762	0.00232	CbGpPWpGaD
Fludarabine—Paraesthesia—Capecitabine—esophageal cancer	0.000762	0.00169	CcSEcCtD
Fludarabine—POLA1—Mitotic M-M/G1 phases—MAD2L1—esophageal cancer	0.000758	0.00231	CbGpPWpGaD
Fludarabine—Dyspnoea—Capecitabine—esophageal cancer	0.000757	0.00168	CcSEcCtD
Fludarabine—POLA1—E2F transcription factor network—CDKN1A—esophageal cancer	0.000755	0.0023	CbGpPWpGaD
Fludarabine—POLA1—Integrated Pancreatic Cancer Pathway—ABL1—esophageal cancer	0.000755	0.0023	CbGpPWpGaD
Fludarabine—RRM1—Integrated Pancreatic Cancer Pathway—BCL2—esophageal cancer	0.000748	0.00227	CbGpPWpGaD
Fludarabine—Dyspepsia—Capecitabine—esophageal cancer	0.000747	0.00165	CcSEcCtD
Fludarabine—DCK—Retinoblastoma (RB) in Cancer—MYC—esophageal cancer	0.000743	0.00226	CbGpPWpGaD
Fludarabine—Decreased appetite—Capecitabine—esophageal cancer	0.000738	0.00163	CcSEcCtD
Fludarabine—RRM1—Metabolism—SLC10A2—esophageal cancer	0.000736	0.00224	CbGpPWpGaD
Fludarabine—RRM1—Metabolism—CA1—esophageal cancer	0.000736	0.00224	CbGpPWpGaD
Fludarabine—Gastrointestinal disorder—Capecitabine—esophageal cancer	0.000733	0.00162	CcSEcCtD
Fludarabine—Vomiting—Cisplatin—esophageal cancer	0.000732	0.00162	CcSEcCtD
Fludarabine—Fatigue—Capecitabine—esophageal cancer	0.000732	0.00162	CcSEcCtD
Fludarabine—POLA1—Integrated Pancreatic Cancer Pathway—SMAD4—esophageal cancer	0.000731	0.00222	CbGpPWpGaD
Fludarabine—POLA1—Integrated Pancreatic Cancer Pathway—ABCB1—esophageal cancer	0.000731	0.00222	CbGpPWpGaD
Fludarabine—RRM1—Integrated Pancreatic Cancer Pathway—ERBB2—esophageal cancer	0.000726	0.00221	CbGpPWpGaD
Fludarabine—Rash—Cisplatin—esophageal cancer	0.000726	0.00161	CcSEcCtD
Fludarabine—Constipation—Capecitabine—esophageal cancer	0.000726	0.00161	CcSEcCtD
Fludarabine—Pain—Capecitabine—esophageal cancer	0.000726	0.00161	CcSEcCtD
Fludarabine—Dermatitis—Cisplatin—esophageal cancer	0.000726	0.00161	CcSEcCtD
Fludarabine—Ill-defined disorder—Methotrexate—esophageal cancer	0.000719	0.00159	CcSEcCtD
Fludarabine—POLA1—E2F transcription factor network—EP300—esophageal cancer	0.000718	0.00218	CbGpPWpGaD
Fludarabine—Anaemia—Methotrexate—esophageal cancer	0.000716	0.00158	CcSEcCtD
Fludarabine—RRM1—Integrated Pancreatic Cancer Pathway—PTGS2—esophageal cancer	0.00071	0.00216	CbGpPWpGaD
Fludarabine—Feeling abnormal—Capecitabine—esophageal cancer	0.0007	0.00155	CcSEcCtD
Fludarabine—Malaise—Methotrexate—esophageal cancer	0.000698	0.00155	CcSEcCtD
Fludarabine—Leukopenia—Methotrexate—esophageal cancer	0.000693	0.00153	CcSEcCtD
Fludarabine—POLA1—S Phase—RB1—esophageal cancer	0.000692	0.0021	CbGpPWpGaD
Fludarabine—POLA1—Integrated Pancreatic Cancer Pathway—BAX—esophageal cancer	0.000692	0.0021	CbGpPWpGaD
Fludarabine—Nausea—Cisplatin—esophageal cancer	0.000684	0.00151	CcSEcCtD
Fludarabine—POLA1—Retinoblastoma (RB) in Cancer—CCND1—esophageal cancer	0.000678	0.00206	CbGpPWpGaD
Fludarabine—Cough—Methotrexate—esophageal cancer	0.000676	0.0015	CcSEcCtD
Fludarabine—RRM1—Metabolism—CA2—esophageal cancer	0.000673	0.00205	CbGpPWpGaD
Fludarabine—Body temperature increased—Capecitabine—esophageal cancer	0.000671	0.00149	CcSEcCtD
Fludarabine—Convulsion—Methotrexate—esophageal cancer	0.000671	0.00149	CcSEcCtD
Fludarabine—DCK—Metabolism—SLC52A3—esophageal cancer	0.000666	0.00203	CbGpPWpGaD
Fludarabine—DCK—Metabolism—BLVRB—esophageal cancer	0.000666	0.00203	CbGpPWpGaD
Fludarabine—POLA1—Mitotic M-M/G1 phases—PSME2—esophageal cancer	0.000666	0.00202	CbGpPWpGaD
Fludarabine—POLA1—Mitotic M-M/G1 phases—PSME1—esophageal cancer	0.000666	0.00202	CbGpPWpGaD
Fludarabine—Myalgia—Methotrexate—esophageal cancer	0.000659	0.00146	CcSEcCtD
Fludarabine—Arthralgia—Methotrexate—esophageal cancer	0.000659	0.00146	CcSEcCtD
Fludarabine—SLC28A3—Transmembrane transport of small molecules—HMOX1—esophageal cancer	0.000659	0.002	CbGpPWpGaD
Fludarabine—POLA1—Retinoblastoma (RB) in Cancer—CDKN1A—esophageal cancer	0.000656	0.002	CbGpPWpGaD
Fludarabine—Discomfort—Methotrexate—esophageal cancer	0.000651	0.00144	CcSEcCtD
Fludarabine—POLA1—Mitotic G1-G1/S phases—RB1—esophageal cancer	0.000643	0.00195	CbGpPWpGaD
Fludarabine—POLA1—Cell Cycle, Mitotic—HIST1H2BM—esophageal cancer	0.000642	0.00195	CbGpPWpGaD
Fludarabine—RRM1—Integrated Pancreatic Cancer Pathway—CCND1—esophageal cancer	0.000642	0.00195	CbGpPWpGaD
Fludarabine—Confusional state—Methotrexate—esophageal cancer	0.000637	0.00141	CcSEcCtD
Fludarabine—SLC28A3—Transmembrane transport of small molecules—ABCB1—esophageal cancer	0.000632	0.00192	CbGpPWpGaD
Fludarabine—Anaphylactic shock—Methotrexate—esophageal cancer	0.000632	0.0014	CcSEcCtD
Fludarabine—Infection—Methotrexate—esophageal cancer	0.000628	0.00139	CcSEcCtD
Fludarabine—RRM1—Metabolism—PLCE1—esophageal cancer	0.000626	0.0019	CbGpPWpGaD
Fludarabine—RRM1—Metabolism—ADH7—esophageal cancer	0.000626	0.0019	CbGpPWpGaD
Fludarabine—POLA1—E2F transcription factor network—MYC—esophageal cancer	0.000626	0.0019	CbGpPWpGaD
Fludarabine—Hypersensitivity—Capecitabine—esophageal cancer	0.000626	0.00138	CcSEcCtD
Fludarabine—RRM1—Integrated Pancreatic Cancer Pathway—CDKN1A—esophageal cancer	0.000621	0.00189	CbGpPWpGaD
Fludarabine—Nervous system disorder—Methotrexate—esophageal cancer	0.00062	0.00137	CcSEcCtD
Fludarabine—Thrombocytopenia—Methotrexate—esophageal cancer	0.000619	0.00137	CcSEcCtD
Fludarabine—Hyperhidrosis—Methotrexate—esophageal cancer	0.000611	0.00135	CcSEcCtD
Fludarabine—DCK—Retinoblastoma (RB) in Cancer—TP53—esophageal cancer	0.00061	0.00186	CbGpPWpGaD
Fludarabine—Asthenia—Capecitabine—esophageal cancer	0.000609	0.00135	CcSEcCtD
Fludarabine—POLA1—Synthesis of DNA—CDKN1A—esophageal cancer	0.000606	0.00184	CbGpPWpGaD
Fludarabine—POLA1—Mitotic M-M/G1 phases—BUB1B—esophageal cancer	0.000606	0.00184	CbGpPWpGaD
Fludarabine—Anorexia—Methotrexate—esophageal cancer	0.000602	0.00133	CcSEcCtD
Fludarabine—Pruritus—Capecitabine—esophageal cancer	0.000601	0.00133	CcSEcCtD
Fludarabine—RRM1—Integrated Pancreatic Cancer Pathway—EP300—esophageal cancer	0.000591	0.0018	CbGpPWpGaD
Fludarabine—Diarrhoea—Capecitabine—esophageal cancer	0.000581	0.00129	CcSEcCtD
Fludarabine—Musculoskeletal discomfort—Methotrexate—esophageal cancer	0.000576	0.00127	CcSEcCtD
Fludarabine—POLA1—Cell Cycle—HIST1H2BM—esophageal cancer	0.000574	0.00175	CbGpPWpGaD
Fludarabine—POLA1—DNA Replication—CDKN1A—esophageal cancer	0.000569	0.00173	CbGpPWpGaD
Fludarabine—Paraesthesia—Methotrexate—esophageal cancer	0.000568	0.00126	CcSEcCtD
Fludarabine—POLA1—Cell Cycle, Mitotic—MAD2L1—esophageal cancer	0.000567	0.00172	CbGpPWpGaD
Fludarabine—DCK—Metabolism—SLC10A2—esophageal cancer	0.000567	0.00172	CbGpPWpGaD
Fludarabine—DCK—Metabolism—CA1—esophageal cancer	0.000567	0.00172	CbGpPWpGaD
Fludarabine—POLA1—Mitotic G1-G1/S phases—CDKN2A—esophageal cancer	0.000565	0.00172	CbGpPWpGaD
Fludarabine—Dyspnoea—Methotrexate—esophageal cancer	0.000563	0.00125	CcSEcCtD
Fludarabine—Adenosine triphosphate—ABCB1—esophageal cancer	0.000561	0.0642	CrCbGaD
Fludarabine—Dyspepsia—Methotrexate—esophageal cancer	0.000556	0.00123	CcSEcCtD
Fludarabine—Decreased appetite—Methotrexate—esophageal cancer	0.000549	0.00122	CcSEcCtD
Fludarabine—RRM1—Metabolism—ADH1B—esophageal cancer	0.000549	0.00167	CbGpPWpGaD
Fludarabine—POLA1—G1/S Transition—CDKN1A—esophageal cancer	0.000548	0.00167	CbGpPWpGaD
Fludarabine—Gastrointestinal disorder—Methotrexate—esophageal cancer	0.000546	0.00121	CcSEcCtD
Fludarabine—Fatigue—Methotrexate—esophageal cancer	0.000545	0.00121	CcSEcCtD
Fludarabine—POLA1—Retinoblastoma (RB) in Cancer—MYC—esophageal cancer	0.000544	0.00165	CbGpPWpGaD
Fludarabine—Pain—Methotrexate—esophageal cancer	0.00054	0.0012	CcSEcCtD
Fludarabine—Vomiting—Capecitabine—esophageal cancer	0.00054	0.0012	CcSEcCtD
Fludarabine—Rash—Capecitabine—esophageal cancer	0.000535	0.00119	CcSEcCtD
Fludarabine—Dermatitis—Capecitabine—esophageal cancer	0.000535	0.00118	CcSEcCtD
Fludarabine—Headache—Capecitabine—esophageal cancer	0.000532	0.00118	CcSEcCtD
Fludarabine—RRM1—Metabolism—TYMP—esophageal cancer	0.000525	0.0016	CbGpPWpGaD
Fludarabine—Feeling abnormal—Methotrexate—esophageal cancer	0.000521	0.00115	CcSEcCtD
Fludarabine—DCK—Metabolism—CA2—esophageal cancer	0.000518	0.00158	CbGpPWpGaD
Fludarabine—RRM1—Integrated Pancreatic Cancer Pathway—MYC—esophageal cancer	0.000515	0.00157	CbGpPWpGaD
Fludarabine—POLA1—S Phase—CCND1—esophageal cancer	0.000514	0.00156	CbGpPWpGaD
Fludarabine—RRM1—Metabolism—CYP26A1—esophageal cancer	0.00051	0.00155	CbGpPWpGaD
Fludarabine—POLA1—Cell Cycle—MAD2L1—esophageal cancer	0.000507	0.00154	CbGpPWpGaD
Fludarabine—Nausea—Capecitabine—esophageal cancer	0.000504	0.00112	CcSEcCtD
Fludarabine—RRM1—Integrated Pancreatic Cancer Pathway—EGFR—esophageal cancer	0.000504	0.00153	CbGpPWpGaD
Fludarabine—Body temperature increased—Methotrexate—esophageal cancer	0.0005	0.00111	CcSEcCtD
Fludarabine—POLA1—Cell Cycle, Mitotic—PSME1—esophageal cancer	0.000498	0.00151	CbGpPWpGaD
Fludarabine—POLA1—Cell Cycle, Mitotic—PSME2—esophageal cancer	0.000498	0.00151	CbGpPWpGaD
Fludarabine—RRM1—Metabolism—ALOX15—esophageal cancer	0.000497	0.00151	CbGpPWpGaD
Fludarabine—POLA1—S Phase—CDKN1A—esophageal cancer	0.000497	0.00151	CbGpPWpGaD
Fludarabine—SLC29A1—Transmembrane transport of small molecules—HMOX1—esophageal cancer	0.000491	0.00149	CbGpPWpGaD
Fludarabine—POLA1—Integrated Pancreatic Cancer Pathway—CASP8—esophageal cancer	0.000491	0.00149	CbGpPWpGaD
Fludarabine—POLA1—Integrated Pancreatic Cancer Pathway—CREBBP—esophageal cancer	0.000489	0.00149	CbGpPWpGaD
Fludarabine—DCK—Metabolism—ADH7—esophageal cancer	0.000482	0.00146	CbGpPWpGaD
Fludarabine—DCK—Metabolism—PLCE1—esophageal cancer	0.000482	0.00146	CbGpPWpGaD
Fludarabine—POLA1—Mitotic G1-G1/S phases—CCND1—esophageal cancer	0.000477	0.00145	CbGpPWpGaD
Fludarabine—RRM1—Metabolism—GSTO1—esophageal cancer	0.000474	0.00144	CbGpPWpGaD
Fludarabine—RRM1—Metabolism—TPI1—esophageal cancer	0.000474	0.00144	CbGpPWpGaD
Fludarabine—SLC29A1—Transmembrane transport of small molecules—ABCB1—esophageal cancer	0.000471	0.00143	CbGpPWpGaD
Fludarabine—Hypersensitivity—Methotrexate—esophageal cancer	0.000466	0.00103	CcSEcCtD
Fludarabine—POLA1—Mitotic G1-G1/S phases—CDKN1A—esophageal cancer	0.000462	0.0014	CbGpPWpGaD
Fludarabine—RRM1—Metabolism—ALDOB—esophageal cancer	0.000455	0.00138	CbGpPWpGaD
Fludarabine—POLA1—G1/S Transition—MYC—esophageal cancer	0.000454	0.00138	CbGpPWpGaD
Fludarabine—Asthenia—Methotrexate—esophageal cancer	0.000453	0.001	CcSEcCtD
Fludarabine—POLA1—Cell Cycle, Mitotic—BUB1B—esophageal cancer	0.000453	0.00138	CbGpPWpGaD
Fludarabine—Pruritus—Methotrexate—esophageal cancer	0.000447	0.00099	CcSEcCtD
Fludarabine—POLA1—Retinoblastoma (RB) in Cancer—TP53—esophageal cancer	0.000447	0.00136	CbGpPWpGaD
Fludarabine—POLA1—Cell Cycle—PSME2—esophageal cancer	0.000445	0.00135	CbGpPWpGaD
Fludarabine—POLA1—Cell Cycle—PSME1—esophageal cancer	0.000445	0.00135	CbGpPWpGaD
Fludarabine—RRM1—Metabolism—GAPDH—esophageal cancer	0.000438	0.00133	CbGpPWpGaD
Fludarabine—RRM1—Integrated Pancreatic Cancer Pathway—PIK3CA—esophageal cancer	0.000437	0.00133	CbGpPWpGaD
Fludarabine—RRM1—Metabolism—CRABP1—esophageal cancer	0.000434	0.00132	CbGpPWpGaD
Fludarabine—Diarrhoea—Methotrexate—esophageal cancer	0.000432	0.000957	CcSEcCtD
Fludarabine—RRM1—Integrated Pancreatic Cancer Pathway—TP53—esophageal cancer	0.000423	0.00129	CbGpPWpGaD
Fludarabine—SLC28A3—Transmembrane transport of small molecules—CREBBP—esophageal cancer	0.000422	0.00128	CbGpPWpGaD
Fludarabine—DCK—Metabolism—ADH1B—esophageal cancer	0.000422	0.00128	CbGpPWpGaD
Fludarabine—POLA1—Integrated Pancreatic Cancer Pathway—BCL2—esophageal cancer	0.000421	0.00128	CbGpPWpGaD
Fludarabine—RRM1—Metabolism—GNG7—esophageal cancer	0.000413	0.00126	CbGpPWpGaD
Fludarabine—POLA1—S Phase—MYC—esophageal cancer	0.000412	0.00125	CbGpPWpGaD
Fludarabine—POLA1—Integrated Pancreatic Cancer Pathway—ERBB2—esophageal cancer	0.000409	0.00124	CbGpPWpGaD
Fludarabine—POLA1—Cell Cycle—BUB1B—esophageal cancer	0.000405	0.00123	CbGpPWpGaD
Fludarabine—DCK—Metabolism—TYMP—esophageal cancer	0.000404	0.00123	CbGpPWpGaD
Fludarabine—Vomiting—Methotrexate—esophageal cancer	0.000402	0.00089	CcSEcCtD
Fludarabine—POLA1—Integrated Pancreatic Cancer Pathway—PTGS2—esophageal cancer	0.0004	0.00122	CbGpPWpGaD
Fludarabine—Rash—Methotrexate—esophageal cancer	0.000398	0.000882	CcSEcCtD
Fludarabine—Dermatitis—Methotrexate—esophageal cancer	0.000398	0.000882	CcSEcCtD
Fludarabine—Headache—Methotrexate—esophageal cancer	0.000396	0.000877	CcSEcCtD
Fludarabine—DCK—Metabolism—CYP26A1—esophageal cancer	0.000393	0.00119	CbGpPWpGaD
Fludarabine—RRM1—Metabolism—ALDH2—esophageal cancer	0.000387	0.00118	CbGpPWpGaD
Fludarabine—POLA1—Cell Cycle—CHEK2—esophageal cancer	0.000386	0.00117	CbGpPWpGaD
Fludarabine—POLA1—Mitotic G1-G1/S phases—MYC—esophageal cancer	0.000383	0.00116	CbGpPWpGaD
Fludarabine—DCK—Metabolism—ALOX15—esophageal cancer	0.000383	0.00116	CbGpPWpGaD
Fludarabine—Nausea—Methotrexate—esophageal cancer	0.000375	0.000831	CcSEcCtD
Fludarabine—RRM1—Metabolism—GSTT1—esophageal cancer	0.000368	0.00112	CbGpPWpGaD
Fludarabine—DCK—Metabolism—TPI1—esophageal cancer	0.000365	0.00111	CbGpPWpGaD
Fludarabine—DCK—Metabolism—GSTO1—esophageal cancer	0.000365	0.00111	CbGpPWpGaD
Fludarabine—RRM1—Metabolism—CYP2A6—esophageal cancer	0.000364	0.00111	CbGpPWpGaD
Fludarabine—POLA1—Integrated Pancreatic Cancer Pathway—CCND1—esophageal cancer	0.000361	0.0011	CbGpPWpGaD
Fludarabine—DCK—Metabolism—ALDOB—esophageal cancer	0.00035	0.00106	CbGpPWpGaD
Fludarabine—POLA1—Integrated Pancreatic Cancer Pathway—CDKN1A—esophageal cancer	0.00035	0.00106	CbGpPWpGaD
Fludarabine—RRM1—Metabolism—ENO1—esophageal cancer	0.000345	0.00105	CbGpPWpGaD
Fludarabine—RRM1—Metabolism—PTGS1—esophageal cancer	0.000345	0.00105	CbGpPWpGaD
Fludarabine—RRM1—Metabolism—PSME1—esophageal cancer	0.00034	0.00103	CbGpPWpGaD
Fludarabine—RRM1—Metabolism—PSME2—esophageal cancer	0.00034	0.00103	CbGpPWpGaD
Fludarabine—DCK—Metabolism—GAPDH—esophageal cancer	0.000337	0.00102	CbGpPWpGaD
Fludarabine—DCK—Metabolism—CRABP1—esophageal cancer	0.000334	0.00102	CbGpPWpGaD
Fludarabine—POLA1—Integrated Pancreatic Cancer Pathway—EP300—esophageal cancer	0.000333	0.00101	CbGpPWpGaD
Fludarabine—DCK—Metabolism—GNG7—esophageal cancer	0.000318	0.000966	CbGpPWpGaD
Fludarabine—POLA1—Mitotic M-M/G1 phases—RB1—esophageal cancer	0.000315	0.000958	CbGpPWpGaD
Fludarabine—SLC29A1—Transmembrane transport of small molecules—CREBBP—esophageal cancer	0.000315	0.000958	CbGpPWpGaD
Fludarabine—DCK—Metabolism—ALDH2—esophageal cancer	0.000298	0.000905	CbGpPWpGaD
Fludarabine—RRM1—Metabolism—CYP1B1—esophageal cancer	0.000293	0.000891	CbGpPWpGaD
Fludarabine—POLA1—Integrated Pancreatic Cancer Pathway—MYC—esophageal cancer	0.00029	0.000882	CbGpPWpGaD
Fludarabine—POLA1—Integrated Pancreatic Cancer Pathway—EGFR—esophageal cancer	0.000284	0.000862	CbGpPWpGaD
Fludarabine—DCK—Metabolism—GSTT1—esophageal cancer	0.000283	0.000861	CbGpPWpGaD
Fludarabine—DCK—Metabolism—CYP2A6—esophageal cancer	0.00028	0.000851	CbGpPWpGaD
Fludarabine—RRM1—Metabolism—CYP19A1—esophageal cancer	0.000276	0.000838	CbGpPWpGaD
Fludarabine—DCK—Metabolism—ENO1—esophageal cancer	0.000265	0.000807	CbGpPWpGaD
Fludarabine—DCK—Metabolism—PTGS1—esophageal cancer	0.000265	0.000807	CbGpPWpGaD
Fludarabine—DCK—Metabolism—PSME1—esophageal cancer	0.000261	0.000795	CbGpPWpGaD
Fludarabine—DCK—Metabolism—PSME2—esophageal cancer	0.000261	0.000795	CbGpPWpGaD
Fludarabine—RRM1—Metabolism—HMOX1—esophageal cancer	0.000251	0.000765	CbGpPWpGaD
Fludarabine—POLA1—Integrated Pancreatic Cancer Pathway—PIK3CA—esophageal cancer	0.000246	0.000749	CbGpPWpGaD
Fludarabine—RRM1—Metabolism—ABCB1—esophageal cancer	0.000241	0.000734	CbGpPWpGaD
Fludarabine—POLA1—Integrated Pancreatic Cancer Pathway—TP53—esophageal cancer	0.000238	0.000724	CbGpPWpGaD
Fludarabine—POLA1—Cell Cycle, Mitotic—RB1—esophageal cancer	0.000236	0.000717	CbGpPWpGaD
Fludarabine—DCK—Metabolism—CYP1B1—esophageal cancer	0.000226	0.000686	CbGpPWpGaD
Fludarabine—DCK—Metabolism—CYP19A1—esophageal cancer	0.000212	0.000645	CbGpPWpGaD
Fludarabine—POLA1—Cell Cycle—RB1—esophageal cancer	0.000211	0.000641	CbGpPWpGaD
Fludarabine—POLA1—Cell Cycle, Mitotic—CDKN2A—esophageal cancer	0.000207	0.00063	CbGpPWpGaD
Fludarabine—DCK—Metabolism—HMOX1—esophageal cancer	0.000194	0.000588	CbGpPWpGaD
Fludarabine—DCK—Metabolism—ABCB1—esophageal cancer	0.000186	0.000565	CbGpPWpGaD
Fludarabine—POLA1—Cell Cycle—CDKN2A—esophageal cancer	0.000185	0.000563	CbGpPWpGaD
Fludarabine—POLA1—Cell Cycle, Mitotic—CCND1—esophageal cancer	0.000175	0.000532	CbGpPWpGaD
Fludarabine—POLA1—Cell Cycle, Mitotic—CDKN1A—esophageal cancer	0.000169	0.000515	CbGpPWpGaD
Fludarabine—RRM1—Metabolism—CREBBP—esophageal cancer	0.000161	0.000491	CbGpPWpGaD
Fludarabine—POLA1—Cell Cycle, Mitotic—EP300—esophageal cancer	0.000161	0.00049	CbGpPWpGaD
Fludarabine—POLA1—Cell Cycle—CCND1—esophageal cancer	0.000156	0.000476	CbGpPWpGaD
Fludarabine—POLA1—Cell Cycle—CDKN1A—esophageal cancer	0.000151	0.00046	CbGpPWpGaD
Fludarabine—RRM1—Metabolism—NOS3—esophageal cancer	0.000144	0.000439	CbGpPWpGaD
Fludarabine—POLA1—Cell Cycle—EP300—esophageal cancer	0.000144	0.000438	CbGpPWpGaD
Fludarabine—POLA1—Cell Cycle, Mitotic—MYC—esophageal cancer	0.00014	0.000427	CbGpPWpGaD
Fludarabine—RRM1—Metabolism—PTGS2—esophageal cancer	0.000132	0.000402	CbGpPWpGaD
Fludarabine—POLA1—Cell Cycle—MYC—esophageal cancer	0.000126	0.000382	CbGpPWpGaD
Fludarabine—DCK—Metabolism—CREBBP—esophageal cancer	0.000124	0.000378	CbGpPWpGaD
Fludarabine—DCK—Metabolism—NOS3—esophageal cancer	0.000111	0.000338	CbGpPWpGaD
Fludarabine—RRM1—Metabolism—EP300—esophageal cancer	0.00011	0.000334	CbGpPWpGaD
Fludarabine—POLA1—Cell Cycle—TP53—esophageal cancer	0.000103	0.000313	CbGpPWpGaD
Fludarabine—DCK—Metabolism—PTGS2—esophageal cancer	0.000102	0.000309	CbGpPWpGaD
Fludarabine—DCK—Metabolism—EP300—esophageal cancer	8.45e-05	0.000257	CbGpPWpGaD
Fludarabine—RRM1—Metabolism—PIK3CA—esophageal cancer	8.13e-05	0.000247	CbGpPWpGaD
Fludarabine—DCK—Metabolism—PIK3CA—esophageal cancer	6.25e-05	0.00019	CbGpPWpGaD
